Home The Word Brain My Amedeo FAQ Privacy About Flying Publisher   


The Angels Initiative

Stroke prevention


  Inflammatory Bowel Diseases

  Free Subscription


Articles published in Lancet Gastroenterol Hepatol

Retrieve available abstracts of 121 articles:
HTML format



Single Articles


    July 2022
  1. ANANTHAKRISHNAN AN, Kaplan GG, Bernstein CN, Burke KE, et al
    Lifestyle, behaviour, and environmental modification for the management of patients with inflammatory bowel diseases: an International Organization for Study of Inflammatory Bowel Diseases consensus.
    Lancet Gastroenterol Hepatol. 2022;7:666-678.
    PubMed     Abstract available


  2. MEIMA-VAN PRAAG EM, van Rijn KL, Wasmann KATGM, Snijder HJ, et al
    Short-term anti-TNF therapy with surgical closure versus anti-TNF therapy in the treatment of perianal fistulas in Crohn's disease (PISA-II): a patient preference randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:617-626.
    PubMed     Abstract available


    June 2022
  3. ROSEIRA J, Estevinho MM, Bernardo S, Sousa P, et al
    Clinical efficacy of endoscopic balloon dilation for Crohn's disease strictures.
    Lancet Gastroenterol Hepatol. 2022;7:503.
    PubMed    


  4. GENERE JR, Deepak P, Kochhar GS
    Reframing self-expandable metal stents for Crohn's strictures.
    Lancet Gastroenterol Hepatol. 2022;7:503-504.
    PubMed    


  5. GELDOF J, Iqbal N, LeBlanc JF, Anandabaskaran S, et al
    Classifying perianal fistulising Crohn's disease: an expert consensus to guide decision-making in daily practice and clinical trials.
    Lancet Gastroenterol Hepatol. 2022;7:576-584.
    PubMed     Abstract available


    May 2022
  6. PARIGI TL, D'Amico F, Abreu MT, Rubin DT, et al
    Difficult-to-treat inflammatory bowel disease: results from a global IOIBD survey.
    Lancet Gastroenterol Hepatol. 2022;7:390-391.
    PubMed    


  7. THE LANCET GASTROENTEROLOGY HE
    Opacity over live vaccines in infants exposed to infliximab.
    Lancet Gastroenterol Hepatol. 2022;7:379.
    PubMed    


    April 2022
  8. WELLENS J, Brann S, Adams A, Marlow L, et al
    Determinants of uptake of a third dose of SARS-CoV-2 vaccines in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2022 Apr 6. pii: S2468-1253(22)00120.
    PubMed    


  9. HAIFER C, Paramsothy S, Kaakoush NO, Leong RW, et al
    Oral faecal microbiota transplantation in ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2022;7:286-287.
    PubMed    


  10. YUAN TY, Rajesh R, Tan M
    Oral faecal microbiota transplantation in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2022;7:286.
    PubMed    


  11. UNGARO RC, Colombel JF
    Treat to target with ustekinumab for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:276-277.
    PubMed    


  12. DANESE S, Vermeire S, D'Haens G, Panes J, et al
    Treat to target versus standard of care for patients with Crohn's disease treated with ustekinumab (STARDUST): an open-label, multicentre, randomised phase 3b trial.
    Lancet Gastroenterol Hepatol. 2022;7:294-306.
    PubMed     Abstract available


  13. LORAS C, Andujar X, Gornals JB, Sanchiz V, et al
    Self-expandable metal stents versus endoscopic balloon dilation for the treatment of strictures in Crohn's disease (ProtDilat study): an open-label, multicentre, randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:332-341.
    PubMed     Abstract available


  14. GOREN I, Rieder F
    Endoscopic interventions for stricturing Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:279-280.
    PubMed    


  15. SCHULBERG JD, Wright EK, Holt BA, Hamilton AL, et al
    Intensive drug therapy versus standard drug therapy for symptomatic intestinal Crohn's disease strictures (STRIDENT): an open-label, single-centre, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2022;7:318-331.
    PubMed     Abstract available


    March 2022
  16. MATSUOKA K, Watanabe M, Ohmori T, Nakajima K, et al
    AJM300 (carotegrast methyl), an oral antagonist of alpha4-integrin, as induction therapy for patients with moderately active ulcerative colitis: a multicentre, randomised, double-blind, placebo-controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2022 Mar 30. pii: S2468-1253(22)00022.
    PubMed     Abstract available


  17. KOTZE PG, Heuthorst L, Lightner AL, Damiao AOMC, et al
    New insights on the surgical management of ulcerative colitis in the 21st century.
    Lancet Gastroenterol Hepatol. 2022 Mar 29. pii: S2468-1253(22)00001.
    PubMed     Abstract available


    February 2022
  18. KUENZIG ME, Widdifield J, Bernatsky S, Kaplan GG, et al
    Uptake of third doses of SARS-CoV-2 vaccines among people with inflammatory bowel disease in Ontario, Canada.
    Lancet Gastroenterol Hepatol. 2022 Feb 22. pii: S2468-1253(22)00054.
    PubMed    


  19. ALEXANDER JL, Kennedy NA, Ibraheim H, Anandabaskaran S, et al
    COVID-19 vaccine-induced antibody responses in immunosuppressed patients with inflammatory bowel disease (VIP): a multicentre, prospective, case-control study.
    Lancet Gastroenterol Hepatol. 2022 Feb 3. pii: S2468-1253(22)00005.
    PubMed     Abstract available


  20. PAPAMICHAEL K, Afif W, Drobne D, Dubinsky MC, et al
    Therapeutic drug monitoring of biologics in inflammatory bowel disease: unmet needs and future perspectives.
    Lancet Gastroenterol Hepatol. 2022;7:171-185.
    PubMed     Abstract available


  21. OZPOLAT HT, Baran B, Akyuz F
    Septic arthritis: a presentation of Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:196.
    PubMed    


    January 2022
  22. GUILLO L, Abreu M, Panaccione R, Sandborn WJ, et al
    Endpoints for extraintestinal manifestations in inflammatory bowel disease trials: the EXTRA consensus from the International Organization for the Study of Inflammatory Bowel Diseases.
    Lancet Gastroenterol Hepatol. 2022 Jan 17. pii: S2468-1253(21)00297.
    PubMed     Abstract available


  23. SASSON AN
    A whole-food exclusion diet as monotherapy for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2022;7:6-7.
    PubMed    


  24. SHEN B, Kochhar GS, Rubin DT, Kane SV, et al
    Treatment of pouchitis, Crohn's disease, cuffitis, and other inflammatory disorders of the pouch: consensus guidelines from the International Ileal Pouch Consortium.
    Lancet Gastroenterol Hepatol. 2022;7:69-95.
    PubMed     Abstract available


  25. YANAI H, Levine A, Hirsch A, Boneh RS, et al
    The Crohn's disease exclusion diet for induction and maintenance of remission in adults with mild-to-moderate Crohn's disease (CDED-AD): an open-label, pilot, randomised trial.
    Lancet Gastroenterol Hepatol. 2022;7:49-59.
    PubMed     Abstract available


    December 2021
  26. HAIFER C, Paramsothy S, Kaakoush NO, Saikal A, et al
    Lyophilised oral faecal microbiota transplantation for ulcerative colitis (LOTUS): a randomised, double-blind, placebo-controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Dec 2. pii: S2468-1253(21)00400.
    PubMed     Abstract available


  27. FISCHER M, Khoruts A
    Oral lyophilised microbiota for the treatment of ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 Dec 2. pii: S2468-1253(21)00433.
    PubMed    


  28. AHMED W, Lukin DJ
    A step towards informed positioning of advanced therapies for moderate-to-severe Crohn's disease.
    Lancet Gastroenterol Hepatol. 2021;6:973-975.
    PubMed    


  29. SO D, Tuck CJ
    Plant-based diets in gastrointestinal disorders: something, nothing, or everything?
    Lancet Gastroenterol Hepatol. 2021;6:992.
    PubMed    


  30. THOMAS H
    UEG Week Virtual 2021.
    Lancet Gastroenterol Hepatol. 2021;6:990.
    PubMed    


  31. SINGH S, Murad MH, Fumery M, Sedano R, et al
    Comparative efficacy and safety of biologic therapies for moderate-to-severe Crohn's disease: a systematic review and network meta-analysis.
    Lancet Gastroenterol Hepatol. 2021;6:1002-1014.
    PubMed     Abstract available


    November 2021
  32. LASA JS, Olivera PA, Danese S, Peyrin-Biroulet L, et al
    Efficacy and safety of biologics and small molecule drugs for patients with moderate-to-severe ulcerative colitis: a systematic review and network meta-analysis.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00377.
    PubMed     Abstract available


  33. MA C, Choi MY
    Integrating novel therapies into the management of moderate-to-severe ulcerative colitis: challenges and opportunities.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00432.
    PubMed    


  34. TAKENAKA K, Fujii T, Kawamoto A, Suzuki K, et al
    Deep neural network for video colonoscopy of ulcerative colitis: a cross-sectional study.
    Lancet Gastroenterol Hepatol. 2021 Nov 29. pii: S2468-1253(21)00372.
    PubMed     Abstract available


  35. PEYRIN-BIROULET L, Hart A, Bossuyt P, Long M, et al
    Etrolizumab as induction and maintenance therapy for ulcerative colitis in patients previously treated with tumour necrosis factor inhibitors (HICKORY): a phase 3, randomised, controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00298.
    PubMed     Abstract available


  36. DANESE S, Colombel JF, Lukas M, Gisbert JP, et al
    Etrolizumab versus infliximab for the treatment of moderately to severely active ulcerative colitis (GARDENIA): a randomised, double-blind, double-dummy, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00294.
    PubMed     Abstract available


  37. VERMEIRE S, Lakatos PL, Ritter T, Hanauer S, et al
    Etrolizumab for maintenance therapy in patients with moderately to severely active ulcerative colitis (LAUREL): a randomised, placebo-controlled, double-blind, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00295.
    PubMed     Abstract available


  38. RUBIN DT, Dotan I, DuVall A, Bouhnik Y, et al
    Etrolizumab versus adalimumab or placebo as induction therapy for moderately to severely active ulcerative colitis (HIBISCUS): two phase 3 randomised, controlled trials.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00338.
    PubMed     Abstract available


  39. AGRAWAL M, Verstockt B
    Etrolizumab for ulcerative colitis: beyond what meets the eye.
    Lancet Gastroenterol Hepatol. 2021 Nov 16. pii: S2468-1253(21)00369.
    PubMed    


  40. MOURAD FH, Hashash JG
    Inflammatory bowel disease in Lebanon: a plea for help.
    Lancet Gastroenterol Hepatol. 2021 Nov 11. pii: S2468-1253(21)00390.
    PubMed    


  41. ASWANI-OMPRAKASH T, Sharma V, Bishu S, Balasubramaniam M, et al
    Addressing unmet needs from a new frontier of IBD: the South Asian IBD Alliance.
    Lancet Gastroenterol Hepatol. 2021;6:884-885.
    PubMed    


    October 2021
  42. SELIM R, Wellens J, Marlow L, Satsangi JJ, et al
    SARS-CoV-2 vaccination uptake by patients with inflammatory bowel disease on biological therapy.
    Lancet Gastroenterol Hepatol. 2021 Oct 13. pii: S2468-1253(21)00347.
    PubMed    


  43. ALEXANDER JL, Selinger CP, Powell N
    Third doses of SARS-CoV-2 vaccines in immunosuppressed patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Oct 12. pii: S2468-1253(21)00374.
    PubMed    


  44. SHEN B, Kochhar GS, Kariv R, Liu X, et al
    Diagnosis and classification of ileal pouch disorders: consensus guidelines from the International Ileal Pouch Consortium.
    Lancet Gastroenterol Hepatol. 2021;6:826-849.
    PubMed     Abstract available


  45. HANAUER S, Liedert B, Balser S, Brockstedt E, et al
    Safety and efficacy of BI 695501 versus adalimumab reference product in patients with advanced Crohn's disease (VOLTAIRE-CD): a multicentre, randomised, double-blind, phase 3 trial.
    Lancet Gastroenterol Hepatol. 2021;6:816-825.
    PubMed     Abstract available


    September 2021
  46. SHEN B, Bortlik M, Bruining DH, Coelho-Prabhu N, et al
    Endoscopic evaluation after surgery in inflammatory bowel disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:691-692.
    PubMed    


  47. SYAL G, Fleshner PR, Melmed GY
    Endoscopic evaluation after surgery in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:690-691.
    PubMed    


  48. KOBAYASHI T
    Stringent criteria for withdrawal of biologics in ulcerative colitis - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:688.
    PubMed    


  49. TAN M, Ng V, Lim CT, Leow WQ, et al
    Stringent criteria for withdrawal of biologics in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021;6:687-688.
    PubMed    


    August 2021
  50. FIORINO G, Allocca M, Danese S
    Adalimumab biosimilar in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Aug 10. pii: S2468-1253(21)00266.
    PubMed    


  51. GEYL S, Guillo L, Laurent V, D'Amico F, et al
    Transmural healing as a therapeutic goal in Crohn's disease: a systematic review.
    Lancet Gastroenterol Hepatol. 2021;6:659-667.
    PubMed     Abstract available


    July 2021
  52. SASSON AN, Ingram RJM, Zhang Z, Taylor LM, et al
    The role of precision nutrition in the modulation of microbial composition and function in people with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021 Jul 13. pii: S2468-1253(21)00097.
    PubMed     Abstract available


  53. GARRIDO HMG, Grobusch MP, D'Haens GRAM, Goorhuis A, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:523.
    PubMed    


  54. ALEXANDER JL, Kennedy NA, Lees CW, Ahmad T, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:523-524.
    PubMed    


  55. DIN S, Gaya DR, Arnott IDR
    COVID-19: Colorectal cancer endoscopic surveillance in IBD.
    Lancet Gastroenterol Hepatol. 2021;6:526-527.
    PubMed    


    June 2021
  56. CROFT NM, Faubion WA Jr, Kugathasan S, Kierkus J, et al
    Efficacy and safety of adalimumab in paediatric patients with moderate-to-severe ulcerative colitis (ENVISION I): a randomised, controlled, phase 3 study.
    Lancet Gastroenterol Hepatol. 2021 Jun 18. pii: S2468-1253(21)00142.
    PubMed     Abstract available


    May 2021
  57. ALEXANDER JL, Powell N
    SARS-CoV-2 vaccination in immunosuppressed patients with inflammatory bowel disease: should our approach change?
    Lancet Gastroenterol Hepatol. 2021 May 25. pii: S2468-1253(21)00184.
    PubMed    


  58. DANESE S, Parigi TL, Peyrin-Biroulet L, Ghosh S, et al
    Defining difficult-to-treat inflammatory bowel disease: why and how.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00141.
    PubMed    


  59. ALSOUD D, Verstockt B, Fiocchi C, Vermeire S, et al
    Breaking the therapeutic ceiling in drug development in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 May 18. pii: S2468-1253(21)00065.
    PubMed     Abstract available


  60. SEGAL JP, Kumar A, Raine T, Lamb CA, et al
    The impact of SARS-CoV-2 variants on IBD management.
    Lancet Gastroenterol Hepatol. 2021;6:343-344.
    PubMed    


    April 2021
  61. UNGAR B
    Infliximab discontinuation in patients with ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00103.
    PubMed    


  62. KOBAYASHI T, Motoya S, Nakamura S, Yamamoto T, et al
    Discontinuation of infliximab in patients with ulcerative colitis in remission (HAYABUSA): a multicentre, open-label, randomised controlled trial.
    Lancet Gastroenterol Hepatol. 2021 Apr 19. pii: S2468-1253(21)00062.
    PubMed     Abstract available


  63. SHEN B, Kochhar GS, Navaneethan U, Cross RK, et al
    Endoscopic evaluation of surgically altered bowel in inflammatory bowel disease: a consensus guideline from the Global Interventional Inflammatory Bowel Disease Group.
    Lancet Gastroenterol Hepatol. 2021 Apr 16. pii: S2468-1253(20)30394.
    PubMed     Abstract available


    March 2021
  64. BARBERIO B, Zamani M, Black CJ, Savarino EV, et al
    Prevalence of symptoms of anxiety and depression in patients with inflammatory bowel disease: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00014.
    PubMed     Abstract available


  65. KEEFER L
    What can we do to tackle anxiety and depression in patients with inflammatory bowel disease?
    Lancet Gastroenterol Hepatol. 2021 Mar 12. pii: S2468-1253(21)00066.
    PubMed    


  66. SEGAL JP, Kayal M, Kochhar G, Dubinsky MC, et al
    The ileoanal pouch: the next frontier in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2021;6:164-165.
    PubMed    


  67. JENA A, Jha DK, Sharma V
    Distinguishing intestinal tuberculosis from Crohn's disease.
    Lancet Gastroenterol Hepatol. 2021;6:159.
    PubMed    


  68. BANERJEE R, Pal P
    Distinguishing intestinal tuberculosis from Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2021;6:159-160.
    PubMed    


    February 2021
  69. SEBASTIAN S, Walker GJ, Kennedy NA, Conley TE, et al
    Assessment, endoscopy, and treatment in patients with acute severe ulcerative colitis during the COVID-19 pandemic (PROTECT-ASUC): a multicentre, observational, case-control study.
    Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00016.
    PubMed     Abstract available


  70. SHEN B
    Acute severe ulcerative colitis: confronting an intensified stressor during the COVID-19 pandemic.
    Lancet Gastroenterol Hepatol. 2021 Feb 2. pii: S2468-1253(21)00009.
    PubMed    


  71. VERMA AM, Patel A, Subramanian S, Smith PJ, et al
    From intravenous to subcutaneous infliximab in patients with inflammatory bowel disease: a pandemic-driven initiative.
    Lancet Gastroenterol Hepatol. 2021;6:88-89.
    PubMed    


    January 2021
  72. ALEXANDER JL, Moran GW, Gaya DR, Raine T, et al
    SARS-CoV-2 vaccination for patients with inflammatory bowel disease: a British Society of Gastroenterology Inflammatory Bowel Disease section and IBD Clinical Research Group position statement.
    Lancet Gastroenterol Hepatol. 2021 Jan 25. pii: S2468-1253(21)00024.
    PubMed     Abstract available


    December 2020
  73. NG SC, Mak JWY, Pal P, Banerjee R, et al
    Optimising management strategies of inflammatory bowel disease in resource-limited settings in Asia.
    Lancet Gastroenterol Hepatol. 2020;5:1089-1100.
    PubMed     Abstract available


  74. BANERJEE R, Pal P, Mak JWY, Ng SC, et al
    Challenges in the diagnosis and management of inflammatory bowel disease in resource-limited settings in Asia.
    Lancet Gastroenterol Hepatol. 2020;5:1076-1088.
    PubMed     Abstract available


  75. STRID H
    Prevalence of IBS-type symptoms in IBD.
    Lancet Gastroenterol Hepatol. 2020;5:1029-1031.
    PubMed    


    November 2020
  76. AZIZ I, Simren M
    The overlap between irritable bowel syndrome and organic gastrointestinal diseases.
    Lancet Gastroenterol Hepatol. 2020 Nov 12. pii: S2468-1253(20)30212.
    PubMed     Abstract available


    October 2020
  77. MA C, Panaccione R
    Harnessing localised delivery of gut-selective therapy for ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30292.
    PubMed    


  78. ATREYA R, Peyrin-Biroulet L, Klymenko A, Augustyn M, et al
    Cobitolimod for moderate-to-severe, left-sided ulcerative colitis (CONDUCT): a phase 2b randomised, double-blind, placebo-controlled, dose-ranging induction trial.
    Lancet Gastroenterol Hepatol. 2020 Oct 5. pii: S2468-1253(20)30301.
    PubMed     Abstract available


  79. AREBI N
    Surgery versus infliximab for Crohn's disease: should there be a change in clinical practice?
    Lancet Gastroenterol Hepatol. 2020;5:877-878.
    PubMed    


  80. BRENNER EJ, Ungaro RC, Colombel JF, Kappelman MD, et al
    IBD in the COVID-19 era: the value of international collaboration.
    Lancet Gastroenterol Hepatol. 2020;5:887-888.
    PubMed    


  81. STEVENS TW, Haasnoot ML, D'Haens GR, Buskens CJ, et al
    Laparoscopic ileocaecal resection versus infliximab for terminal ileitis in Crohn's disease: retrospective long-term follow-up of the LIR!C trial.
    Lancet Gastroenterol Hepatol. 2020;5:900-907.
    PubMed     Abstract available


  82. FAIRBRASS KM, Costantino SJ, Gracie DJ, Ford AC, et al
    Prevalence of irritable bowel syndrome-type symptoms in patients with inflammatory bowel disease in remission: a systematic review and meta-analysis.
    Lancet Gastroenterol Hepatol. 2020 Oct 1. pii: S2468-1253(20)30300.
    PubMed     Abstract available


    September 2020
  83. KUMAR A, Quraishi MN, Segal JP, Raine T, et al
    COVID-19 vaccinations in patients with inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2020 Sep 21. pii: S2468-1253(20)30295.
    PubMed    


  84. RAINE T, Verstockt B, De Cruz P
    Immune therapies in ulcerative colitis: are we beyond anti-TNF yet?
    Lancet Gastroenterol Hepatol. 2020;5:794-796.
    PubMed    


  85. SLEUTJES JAM, de Vries AC, van der Woude CJ
    Ozanimod in Crohn's disease: a promising new player.
    Lancet Gastroenterol Hepatol. 2020;5:791-792.
    PubMed    


  86. FEAGAN BG, Sandborn WJ, Danese S, Wolf DC, et al
    Ozanimod induction therapy for patients with moderate to severe Crohn's disease: a single-arm, phase 2, prospective observer-blinded endpoint study.
    Lancet Gastroenterol Hepatol. 2020;5:819-828.
    PubMed     Abstract available


    August 2020
  87. NGUYEN LH, Ortqvist AK, Cao Y, Simon TG, et al
    Antibiotic use and the development of inflammatory bowel disease: a national case-control study in Sweden.
    Lancet Gastroenterol Hepatol. 2020 Aug 17. pii: S2468-1253(20)30267.
    PubMed     Abstract available


  88. SOKOL H
    Antibiotics: a trigger for inflammatory bowel disease?
    Lancet Gastroenterol Hepatol. 2020 Aug 17. pii: S2468-1253(20)30208.
    PubMed    


  89. RUDDY J, Taft T, Siau K, Bollipo S, et al
    Emotional state should not be used to differentiate IBD from IBS.
    Lancet Gastroenterol Hepatol. 2020;5:723.
    PubMed    


  90. IACUCCI M, Cannatelli R, Labarile N, Ghosh S, et al
    Emotional state should not be used to differentiate IBD from IBS - Authors' reply.
    Lancet Gastroenterol Hepatol. 2020;5:723-724.
    PubMed    


    July 2020
  91. DING NS, An P, Dong W, Ding Y, et al
    Prevention of COVID-19 in patients with IBD - Authors' reply.
    Lancet Gastroenterol Hepatol. 2020;5:640-641.
    PubMed    


    June 2020
  92. ORR WC, Fass R, Sundaram SS, Scheimann AO, et al
    The effect of sleep on gastrointestinal functioning in common digestive diseases.
    Lancet Gastroenterol Hepatol. 2020;5:616-624.
    PubMed     Abstract available


    May 2020
  93. SEGAL JP, Quraishi MN, Bhala N, Brookes MJ, et al
    Prevention of COVID-19 in patients with IBD.
    Lancet Gastroenterol Hepatol. 2020 May 19. pii: S2468-1253(20)30153.
    PubMed    


  94. FIORINO G, Peyrin-Biroulet L, Danese S
    Protecting patients with IBD during the COVID-19 pandemic.
    Lancet Gastroenterol Hepatol. 2020 May 19. pii: S2468-1253(20)30152.
    PubMed    


  95. CHEN Y, Hu S, Wu H, Farraye FA, et al
    Patterns of care for inflammatory bowel disease in China during the COVID-19 pandemic.
    Lancet Gastroenterol Hepatol. 2020 May 13. pii: S2468-1253(20)30131.
    PubMed    


  96. D'AMICO F, Rahier JF, Leone S, Peyrin-Biroulet L, et al
    Views of patients with inflammatory bowel disease on the COVID-19 pandemic: a global survey.
    Lancet Gastroenterol Hepatol. 2020 May 13. pii: S2468-1253(20)30151.
    PubMed    


  97. HAN J, Zhu L, Wang Y, Zeng Z, et al
    Resumption of daily services in a gastroenterology department in Guangzhou, China, in the wake of COVID-19.
    Lancet Gastroenterol Hepatol. 2020 May 4. pii: S2468-1253(20)30133.
    PubMed    


  98. SELINGER CP
    Biologicals are the main contributor to cost of care for IBD: a European perspective.
    Lancet Gastroenterol Hepatol. 2020;5:421-422.
    PubMed    


  99. LOUGHMAN A, Staudacher HM
    Treating the individual with diet: is gut microbiome testing the answer?
    Lancet Gastroenterol Hepatol. 2020;5:437.
    PubMed    


    April 2020
  100. AN P, Ji M, Ren H, Su J, et al
    Prevention of COVID-19 in patients with inflammatory bowel disease in Wuhan, China.
    Lancet Gastroenterol Hepatol. 2020 Apr 17. pii: S2468-1253(20)30121.
    PubMed    


  101. IACUCCI M, Cannatelli R, Labarile N, Mao R, et al
    Endoscopy in inflammatory bowel diseases during the COVID-19 pandemic and post-pandemic period.
    Lancet Gastroenterol Hepatol. 2020 Apr 16. pii: S2468-1253(20)30119.
    PubMed     Abstract available


  102. MUSHTAQ A, Kazi F
    Switching to biosimilars: boon or bust?
    Lancet Gastroenterol Hepatol. 2020;5:341-342.
    PubMed    


    March 2020
  103. ZINGONE F, Savarino EV
    Viral screening before initiation of biologics in patients with inflammatory bowel disease during the COVID-19 outbreak.
    Lancet Gastroenterol Hepatol. 2020 Mar 25. pii: S2468-1253(20)30085.
    PubMed    


  104. SHIVAJI UN, Nardone OM, Cannatelli R, Smith SC, et al
    Small molecule oral targeted therapies in ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2020 Mar 11. pii: S2468-1253(19)30414.
    PubMed     Abstract available


  105. MAO R, Liang J, Shen J, Ghosh S, et al
    Implications of COVID-19 for patients with pre-existing digestive diseases.
    Lancet Gastroenterol Hepatol. 2020 Mar 11. pii: S2468-1253(20)30076.
    PubMed    


  106. OLESEN SW, Panchal P, Chen J, Budree S, et al
    Global disparities in faecal microbiota transplantation research.
    Lancet Gastroenterol Hepatol. 2020;5:241.
    PubMed    


    February 2020
  107. BURISCH J, Vardi H, Schwartz D, Friger M, et al
    Health-care costs of inflammatory bowel disease in a pan-European, community-based, inception cohort during 5 years of follow-up: a population-based study.
    Lancet Gastroenterol Hepatol. 2020 Feb 13. pii: S2468-1253(20)30012.
    PubMed     Abstract available


  108. HOU JK
    Colorectal cancer in Crohn's disease: closing the gap.
    Lancet Gastroenterol Hepatol. 2020 Feb 13. pii: S2468-1253(20)30046.
    PubMed    


  109. OLEN O, Erichsen R, Sachs MC, Pedersen L, et al
    Colorectal cancer in Crohn's disease: a Scandinavian population-based cohort study.
    Lancet Gastroenterol Hepatol. 2020 Feb 13. pii: S2468-1253(20)30005.
    PubMed     Abstract available


  110. HASTINGS B
    Successful control of ulcerative colitis.
    Lancet Gastroenterol Hepatol. 2020;5:116.
    PubMed    


    January 2020
  111. SHEN B, Kochhar G, Navaneethan U, Farraye FA, et al
    Practical guidelines on endoscopic treatment for Crohn's disease strictures: a consensus statement from the Global Interventional Inflammatory Bowel Disease Group.
    Lancet Gastroenterol Hepatol. 2020 Jan 16. pii: S2468-1253(19)30366.
    PubMed     Abstract available


  112. CHAPMAN TP, Gomes CF, Louis E, Colombel JF, et al
    De-escalation of immunomodulator and biological therapy in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2020;5:63-79.
    PubMed     Abstract available


  113. NOOR NM, Verstockt B, Parkes M, Lee JC, et al
    Personalised medicine in Crohn's disease.
    Lancet Gastroenterol Hepatol. 2020;5:80-92.
    PubMed     Abstract available


    December 2019
  114. WALJEE AK, Higgins PDR, Jensen CB, Villumsen M, et al
    Anti-tumour necrosis factor-alpha therapy and recurrent or new primary cancers in patients with inflammatory bowel disease, rheumatoid arthritis, or psoriasis and previous cancer in Denmark: a nationwide, population-based cohort study.
    Lancet Gastroenterol Hepatol. 2019 Dec 10. pii: S2468-1253(19)30362.
    PubMed     Abstract available


  115. IACUCCI M, Cannatelli R, Tontini GE, Panaccione R, et al
    Improving the quality of surveillance colonoscopy in inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2019;4:971-983.
    PubMed     Abstract available


  116. O'KEEFE SJ
    The association between dietary fibre deficiency and high-income lifestyle-associated diseases: Burkitt's hypothesis revisited.
    Lancet Gastroenterol Hepatol. 2019;4:984-996.
    PubMed     Abstract available


    November 2019
  117. D'HAENS G, Pinzani M
    Intestinal and hepatic fibrosis: how are they similar?
    Lancet Gastroenterol Hepatol. 2019;4:820-822.
    PubMed    


    October 2019
  118. JAIRATH V, Feagan BG
    Global burden of inflammatory bowel disease.
    Lancet Gastroenterol Hepatol. 2019 Oct 21. pii: S2468-1253(19)30358.
    PubMed    



  119. The global, regional, and national burden of inflammatory bowel disease in 195 countries and territories, 1990-2017: a systematic analysis for the Global Burden of Disease Study 2017.
    Lancet Gastroenterol Hepatol. 2019 Oct 21. pii: S2468-1253(19)30333.
    PubMed     Abstract available


    February 2019
  120. TAYLOR SA, Halligan S, Bhatnagar G, Gupta A, et al
    Diagnostic accuracy of MRE and ultrasound for Crohn's disease - Authors' reply.
    Lancet Gastroenterol Hepatol. 2019;4:96.
    PubMed    


  121. NOVAK K, Maaser C, Wilkens R, Maconi G, et al
    Diagnostic accuracy of MRE and ultrasound for Crohn's disease.
    Lancet Gastroenterol Hepatol. 2019;4:95-96.
    PubMed    


Thank you for your interest in scientific medicine.


AMEDEO Inflammatory Bowel Diseases is free of charge.
This policy is made possible thanks to a media sponsorship by Boehringer Ingelheim.

Design: